000661 Changchun High-Tech Industries
- 117.47
- +0.42+0.36%
Changchun High-Tech Industries News
Changchun Hi-Tech (000661.SZ): The main business is R&D, production and sales of biopharmaceuticals and proprietary Chinese medicines
Gelonghui, May 9丨Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that synthetic biology is an emerging discipline based on engineering design concepts, combining interdisciplinary technologies such as biology, chemistry, medicine, engineering, computer and data science, to transform or create artificial life systems. Currently, the company's main business is R&D, production and sales of biopharmaceuticals and proprietary Chinese medicines. The business segment covers various pharmaceutical segments such as genetic engineering, biological vaccines, antibody drugs, high-end chemicals, modern traditional Chinese medicine, etc. The company will actively pay attention to industry and technological progress, and according to the actual situation and development plans
Investors Don't See Light At End Of Changchun High-Tech Industry (Group) Co., Ltd.'s (SZSE:000661) Tunnel
With a price-to-earnings (or "P/E") ratio of 10x Changchun High-Tech Industry (Group) Co., Ltd. (SZSE:000661) may be sending very bullish signals at the moment, given that almost half of all companies
Changchun Hi-Tech (000661.SZ) subsidiary's application for marketing licensing of Baike Bio's live attenuated nasal spray influenza vaccine was accepted
Changchun Hi-Tech (000661.SZ) issued an announcement. The company's subsidiary Changchun Baike Biotechnology Co., Ltd. (abbreviated as “...
Changchun Hi-Tech (000661.SZ): Net profit of 859 million yuan in the first quarter increased 0.20% year-on-year
Gelonghui, April 19 | Changchun Hi-Tech (000661.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 3.177 billion yuan, up 14.39% year on year; net profit attributable to shareholders of listed companies was 859 million yuan, up 0.20% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 847 million yuan, down 0.86% year on year; basic earnings per share were 2.13 yuan.
Changchun Hi-Tech (000661.SZ): Application for marketing of injectable triprorelin acetate microspheres accepted
Gelonghui, April 18 | Changchun Hi-Tech (000661.SZ) announced, Changchun Hi-Tech (000661.SZ) announced that the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. received the “Notice of Acceptance” approved and issued by the State Drug Administration, and Jinsai Pharmaceutical's marketing application for injectable triprorelin acetate microspheres was accepted. The company's injectable triprorelin acetate microsphere products improve drug safety by improving drug release characteristics, optimizing prescriptions and processes, and making it possible for pediatric patients to administer fixed doses. A more convenient method of administration supported by evidence-based medical evidence will be central precocious puberty (C
Declining Stock and Solid Fundamentals: Is The Market Wrong About Changchun High-Tech Industries (Group) Inc. (SZSE:000661)?
Changchun High-Tech Industries (Group) (SZSE:000661) has had a rough month with its share price down 9.8%. However, stock prices are usually driven by a company's financial performance over the long
Changchun Hi-Tech (000661.SZ) plans to pay 45 yuan for 10 shares to be deducted from interest on April 18
Changchun Hi-Tech (000661.SZ) announced that the company's 2023 equity distribution plan: 45 yuan for every 10 shares...
Changchun Hi-Tech (000661.SZ): In the field of drug research and development, it has built various R&D innovation technology platforms, including long-term controlled release technology platforms for protein drugs, ADC drug technology platforms, special f
Gelonghui, March 28 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that the company adheres to product development and introduction strategies with technological innovation as the lead, market demand as the guide, and clinical application value as the core, and continuously optimizes product iterations. In recent years, while ensuring stable performance, the company has rapidly raised the level of R&D investment, improved pipeline layout in multiple fields, actively expanded technical coverage, promoted global layout, promoted technological upgrading and process optimization of existing products, continuously enhanced multi-level R&D pipelines and rich project reserves, and strengthened the construction of innovative technology platforms. Built in the field of drug development
Changchun Hi-Tech (000661.SZ): The share of the company's long-term water needles in growth hormone product revenue has increased to about 29% in 2023
Gelonghui March 25 丨 Changchun Hi-Tech (000661.SZ) held a performance briefing on March 25, 2024. Regarding “What is the current sales share of long-lasting growth hormone?” The company replied that in 2023, the company's share of growth hormone product revenue for long-acting water injections had increased to about 29%.
Changchun Hi-Tech (000661.SZ): Currently, the company's EG017 ointment is used for patients with dry eye and other indications in phase II clinical trials and continues to enroll
Gelonghui, March 25: An investor asked Changchun Hi-Tech (000661.SZ) on the investor interactive platform, “Can we talk about whether Gaoxin will enter the field of ophthalmology in the future?” The company replied that currently the company's EG017 ointment is used for patients with indications such as dry eye and phase II clinical trials.
Changchun High-Tech Industries (Group) Inc. Just Missed EPS By 6.6%: Here's What Analysts Think Will Happen Next
The annual results for Changchun High-Tech Industries (Group) Inc. (SZSE:000661) were released last week, making it a good time to revisit its performance. Revenues of CN¥15b were in line with f
2024 Financial Report | Profit growth hit its lowest level in 10 years. Is Changchun Gaoxin's growth hormone ceiling here?
The time for the “first strain of growth hormone” to slow down has arrived. On March 20, Changchun Hi-Tech (000661.SZ) released its 2023 financial report, showing that current revenue and net profit to mother were 14.566 billion yuan and 4.532 billion yuan respectively, up 15.35% and 9.47% year-on-year respectively. This net profit growth rate to mother hit a record low since 2014. On March 20, Changchun Hi-Tech closed down 2.57%. Specifically, the current revenue and net revenue of Changchun Jinsai Pharmaceutical Co., Ltd. (hereinafter referred to as “Jinsai Pharmaceutical”), the core subsidiary responsible for growth hormone under Changchun Hi-Tech
Changchun High & New Technology's 2023 Profit Rises 9.5% on Higher Revenue
Changchun High & New Technology Industries Group's (SHE:000661) attributable profit rose 9.47% to 4.53 billion yuan in 2023 from 4.14 billion yuan in 2022, according to a Wednesday filing with the She
Changchun Hi-Tech (000661.SZ): Net profit for 2023 increased 9.47% to 4,532 billion yuan, plans to distribute 10 to 45 yuan
Gelonghui, March 19 | Changchun Hi-Tech (000661.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 14.566 billion yuan, up 15.35% year on year; net profit attributable to shareholders of listed companies was 4.532 billion yuan, up 9.47% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4,516 billion yuan, up 9.63% year on year; basic income per share was 11.21 yuan; plans to distribute a cash dividend of 45 yuan (tax included) to all shareholders for every 10 shares
Changchun Hi-Tech (000661.SZ): Currently, some PEGs are for personal use
Gelonghui March 19 丨 An investor asked Changchun Hi-Tech (000661.SZ) on the investor interactive platform, “Does the company already use its own PEG? If not, why?” The company replied that currently some of the PEGs are for personal use.
Institutions Own 25% of Changchun High-Tech Industries (Group) Inc. (SZSE:000661) Shares but Retail Investors Control 47% of the Company
Key Insights Changchun High-Tech Industries (Group)'s significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 inves
Changchun Hi-Tech (000661.SZ): Currently, the company accounts for a relatively small share of overseas revenue
Gelonghui March 8 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that the company currently accounts for a relatively small share of overseas revenue.
Changchun Hi-Tech (000661.SZ): Actively pay attention to the application of growth hormone products in the adult domain
Gelonghui, March 8 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that according to relevant expert consensus, recombinant human growth hormone treatment can improve clinical symptoms and reduce the occurrence of related complications in patients with growth hormone deficiency, including improving body composition and exercise capacity, reducing cardiovascular risk, increasing bone quality, and improving quality of life. The company actively pays attention to the application of growth hormone products in the adult sector, and is steadily promoting sales, promotion, research and development of related products.
Changchun Hi-Tech (000661.SZ): Steadily promoting children's health-related devices and products
Gelonghui, March 8 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that the company is steadily promoting children's health-related equipment products, etc. For details on the current layout and future development plans, please pay attention to the company's regular reports, etc.
Changchun Hi-Tech (000661.SZ): Currently, the company's long-acting liquid agent is the only growth hormone product approved for sale in China
Gelonghui, Feb. 20 | Changchun Hi-Tech (000661.SZ) said on the investor interactive platform that currently the company's long-acting liquid agent is the only growth hormone product approved for sale in China, and there are other companies' products approved for sale in powder and water products.
Analysis
Price Target
No Data
